FDA Permits Marketing of First Game-Based Digital Therapeutic to Improve Attention Function in Children with ADHD

FDAThe U.S. Food and Drug Administration (FDA) permitted marketing of the first game-based digital therapeutic device to improve attention function in children with attention deficit hyperactivity disorder (ADHD). The prescription-only game-based device, called EndeavorRx, is indicated for pediatric patients ages 8 to12 years old with primarily inattentive or combined-type ADHD who have demonstrated an attention issue. EndeavorRx is indicated to improve attention function as measured by computer-based testing and is the first digital therapeutic intended to improve symptoms associated with ADHD, as well as the first game-based therapeutic granted marketing authorization by the FDA for any type of condition. The device is intended for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder.

"The EndeavorRx device offers a non-drug option for improving symptoms associated with ADHD in children and is an important example of the growing field of digital therapy and digital therapeutics," said Jeffrey Shuren, M.D., J.D., director of the FDA's Center for Devices and Radiological Health. "The FDA is committed to providing regulatory pathways that enable patients timely access to safe and effective innovative digital therapeutics."

ADHD is a common disorder that begins in childhood, affecting approximately 4 million children ages 6-11. Symptoms include difficulty staying focused and paying attention, difficulty controlling behavior, and very high levels of activity. According to the Centers for Disease Control and Prevention, diagnosis of ADHD should be conducted by a trained health care professional and follow an evaluation of symptoms or pattern of symptoms, such as inattention, hyperactivity, and impulsivity that interfere with functioning or development.

The FDA reviewed data from multiple studies in more than 600 children, including studies that evaluated, among other things, whether participants demonstrated improvements in attention function, as measured by the Test of Variables of Attention (TOVA), academic performance measures, and other assessment tools. There were no serious adverse events reported. The most common adverse events observed with EndeavorRx are: frustration, headache, dizziness, emotional reaction, and aggression.

The FDA reviewed the EndeavorRx through the De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. This action creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA's 510(k) premarket notification process, whereby devices can obtain marketing authorization by demonstrating substantial equivalence to a predicate device.

The FDA granted marketing authorization for the EndeavorRx to Akili Interactive.

About FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Most Popular Now

Hull University Teaching Hospitals NHS T…

Hull University Teaching Hospitals NHS Trust has deployed DXC Technology's (NYSE:DXC) cloud-based Clinical Aide mobile application, which both improves secure access to electronic patient medical records and increases patient and...

Central Hospital in Finland Automates Sy…

This November Central Ostrobothnia Central Hospital in Finland has started symptom tracking and remote monitoring of corona virus-infected patients with the Buddy Healthcare mobile application and clinical monitoring platform. The...

Ultrapotent COVID-19 Vaccine Candidate D…

An innovative nanoparticle vaccine candidate for the pandemic coronavirus produces virus-neutralizing antibodies in mice at levels ten-times greater than is seen in people who have recovered from COVID-19 infections. Designed...

Interactive virtual reality emerges as a…

Bristol scientists have demonstrated a new virtual reality [VR] technique which should help in developing drugs against the SARS-CoV-2 virus - and enable researchers to share models and collaborate in...

More than 1,000 Exhibitors have Already …

16 - 19 November 2020, Düsseldorf, Germany. This year, the world's largest and leading medical trade fair, MEDICA, and the number one international event for the medical technology manufacturing supplier market...

Softphone App to Save NHS up to £20 Mill…

GPs and patients are to benefit from a new softphone app that will eliminate almost all the "hidden cost" of calls for remote consultations and is forecast to save the...

DMEA Newcomer Award: The Search is on fo…

13 - 15 April 2021, Berlin, Germany. More efficient, digital and patient-friendly! Tomorrow's healthcare system promises great things. And to ensure this becomes reality a fresh impetus and creative ideas are...

App to Help NHS Prevent Deadly Hospital …

Compass app to help NHS trusts prevent hospital-acquired acute kidney injury and pneumonia - both of which cause harm to COVID-19 patients and can be fatal. Hospitals could alleviate pressure...

Leeds Deploys Imaging Tech for Advanced …

A multi-million pound initiative that is digitising, connecting and applying artificial intelligence to NHS pathology services in the North of England has taken an important step, after Leeds Teaching Hospitals...

Survey of COVID-19 Research Provides Fre…

Researchers at Karolinska Institutet in Sweden have explored all COVID-19 research published during the initial phase of the pandemic. The results, which were achieved by using a machine learning-based approach...

COVID-19 High Performance Computing Cons…

The COVID-19 High Performance Computing (HPC) Consortium, a unique public-private effort to make supercomputing power available to researchers working on projects related to COVID-19, announced that it has entered into...